Oramed Pharmaceuticals Inc. (ORMP)


NasdaqCM - NasdaqCM Real Time Price. Currency in USD
7.62+0.02 (+0.26%)
At close: 4:00 PM EDT
People also watch:
OHRPCNATVBLTCANFADHD
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Open7.59
Prev Close7.60
Bid6.14 x 100
Ask14.50 x 4600
Day's Range7.51 - 7.64
52wk Range5.40 - 10.74
1y Target EstN/A
Market Cap100.1M
P/E Ratio (ttm)-11.19
Beta0.58
Volume21,928
Avg Vol (3m)53,023
Dividend & YieldN/A (N/A)
Earnings DateN/A
Trade prices are not sourced from all markets
  • Oramed (ORMP) Reports Additional Positive Data from Phase IIb ORMD-0801 Study
    Zacks Small Cap Research16 days ago

    Oramed (ORMP) Reports Additional Positive Data from Phase IIb ORMD-0801 Study

    ORA-D-007 is a double-blind, randomized, 28-day Phase IIb clinical trial designed to assess the safety and efficacy of ORMD-0801 in type II diabetics. The trial will evaluate ORMD-0801 over a longer treatment period (28-day vs 7-day in the Phase IIa study) and will have statistical power to give greater insight into the drug’s efficacy.

  • The Cryptic World of Oral Insulin, Novo Nordisk A/S (ADR) (NVO) vs Oramed Pharmaceuticals, Inc. (ORMP)
    Insider Monkey18 days ago

    The Cryptic World of Oral Insulin, Novo Nordisk A/S (ADR) (NVO) vs Oramed Pharmaceuticals, Inc. (ORMP)

    The problem with being at the top of one of the largest healthcare market niches in the world is extremely heightened expectations. The World Health Organization (WHO) estimates that the annual cost of diabetes to the world is $827 billion. That’s nearly one trillion dollars, every year, year in year out. To be on the […]

  • PR Newswire25 days ago

    Oramed Receives Additional $4 Million Milestone Payment From HTIT

    Oramed Pharmaceuticals Inc. (ORMP) (http://www.oramed.com), a developer of oral drug delivery systems, today announced it has received a milestone payment of $4 million from Hefei Tianhui Incubator of Technologies Co. Ltd. (HTIT). This milestone, part of a previously-announced license and investment agreement between Oramed and HTIT, follows Oramed's report of additional positive efficacy and safety data from its recently completed Phase IIb trial of its oral insulin product, ORMD-0801. "China is currently the largest single diabetes population in the world," stated Oramed CEO Nadav Kidron.